Next generation therapies change the landscape in melanoma
نویسندگان
چکیده
منابع مشابه
Next generation therapies change the landscape in melanoma
Melanoma is among the leading causes of years of life lost due to cancer. Current chemotherapy and cytokine-based immunotherapy approaches benefit only a small percentage of patients with advanced disease. However, the recent discovery of mutations in the gene encoding the serine-threonine kinase B-RAF (BRAF) raises the possibility that oncogene-targeted therapy may provide a new point of vulne...
متن کاملNext-Generation Sequencing: Targeting Targeted Therapies.
Next-generation sequencing (NGS) has given new perspective in oncology. With the ongoing development of targeted therapies, NGS is evolving molecular diagnostics by providing comprehensive interrogation of clinically actionable genomic aberrations in tumors. Having this assay as the primary testing method produces clinically beneficial results. See related article by Drilon et al., p. 3631.
متن کاملBio-Informatics - Next Generation Cancer Targeted Therapies
Since its birth in the 1980s, bio-informatics has been rapidly growing, keeping pace with the expansion of genome sequence data. Latest technological development of large-scale gene expression analysis using DNA micro-arrays and proteomics experiments has further boosted the importance of bio-informatics methods. In Bio-Informatics a lot of tools & algorithms are developed to study detailed sha...
متن کاملLandscape of next-generation sequencing technologies.
Landscape of Next-Generation Sequencing Technologies Thomas P. Niedringhaus, Denitsa Milanova, Matthew B. Kerby, Michael P. Snyder, and Annelise E. Barron* Department of Chemical Engineering, Stanford University, Palo Alto, California, United States Department of Mechanical Engineering, Stanford University, Palo Alto, California, United States Department of Bioengineering, Stanford University, ...
متن کاملLatest Approved Therapies for Metastatic Melanoma: What Comes Next?
Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: F1000 Medicine Reports
سال: 2011
ISSN: 1757-5931
DOI: 10.3410/m3-8